Back to Journals » Drug Design, Development and Therapy » Volume 13

Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives

Authors Bimonte S, Albino V, Piccirillo M, Nasto A, Molino C, Palaia R, Cascella M

Received 13 July 2018

Accepted for publication 14 August 2018

Published 12 February 2019 Volume 2019:13 Pages 611—621

DOI https://doi.org/10.2147/DDDT.S180079

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng


Sabrina Bimonte,1 Vittorio Albino,2 Mauro Piccirillo,2 Aurelio Nasto,3 Carlo Molino,4 Raffaele Palaia,2 Marco Cascella1

1Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS – Fondazione G Pascale, Naples, Italy; 2Division of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori, IRCCS – Fondazione G Pascale, Naples, Italy; 3UOC Chirurgia Generale ad Indirizzo Oncologico, POA Tortora, Pagani, Salerno, Italy; 4A Cardarelli Chirurgia Generale – AORN, Naples, Italy

Abstract: Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.

Keywords: hepatocellular carcinoma, epigallocatechin-3-gallate, tumor progression, preclinical studies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]